keyword
MENU ▼
Read by QxMD icon Read
search

fibrosis hcv

keyword
https://www.readbyqxmd.com/read/29774570/high-mobility-group-box-1-drives-fibrosis-progression-signaling-via-the-receptor-for-advanced-glycation-end-products-in-mice
#1
Xiaodong Ge, Elena Arriazu, Fernando Magdaleno, Daniel J Antoine, Rouchelle Dela Cruz, Neil Theise, Natalia Nieto
BACKGROUND & RATIONALE: High-mobility group box-1 (HMGB1) is a damage-associated molecular pattern (DAMP) increased in response to liver injury. Since HMGB1 is a ligand for the receptor for advanced glycation end-products (RAGE), we hypothesized that induction of HMGB1 could participate in the pathogenesis of liver fibrosis via RAGE cell-specific signaling mechanisms. RESULTS: liver HMGB1 protein expression correlated with fibrosis stage in patients with chronic Hepatitis C virus (HCV) infection, primary biliary cirrhosis (PBC) and alcoholic steatohepatitis (ASH)...
May 18, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29773081/long-term-familial-mediterranean-fever-remission-on-successful-hepatitis-c-virus-treatment-in-a-patient-not-responding-to-colchicine-a-case-report
#2
Manik Gemilyan, Gagik Hakobyan, Susanna Ananyan
BACKGROUND: Familial Mediterranean fever is an autosomal recessive disorder characterized by periodic febrile attacks of aseptic serositis and/or arthritis. The main treatment is colchicine which prevents attacks in the majority of patients except for a group of colchicine-resistant cases. Chronic hepatitis C is a viral infection causing chronic inflammation of liver tissue (hepatitis) which ultimately progresses to fibrosis and liver cirrhosis with a high chance of hepatocellular carcinoma...
May 18, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#3
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29765541/the-effect-of-antiviral-therapy-on-serum-lipid-profiles-in-chronic-hepatitis-c
#4
Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Nei-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Chia-Yen Dai
Background: Low lipid profile is associated with hepatitis C virus (HCV) infection. Chronic HCV infection is the main cause of liver injury and serum lipid levels during antiviral treatment. We aimed to evaluate the effect of antiviral treatment on the change of lipid profiles during HCV treatment. Methods: Total 863 patients who complete the interferon-based therapy in Kaohsiung Medical University Hospital were included in this study. The lipid profile measured and evaluated in baseline and after 6 months of the treatment...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29755014/diagnosis-of-cirrhosis-in-patients-with-chronic-hepatitis-c-genotype-4-role-of-abcb11-genotype-polymorphism-and-plasma-bile-acid-levels
#5
Tarek Besheer, Mona Arafa, Mohamed Abd El-Maksoud, Hatem Elalfy, Amany Hasson, Khaled Zalata, Wagdi Elkashef, Heba Elshahawy, Doaa Raafat, Wafaa Elemshaty, Eman Elsayed, Hosam Zaghloul, Ahmed Abdel Razek, Mahmoud El-Bendary
BACKGROUND/AIMS: Chronic hepatitis C (CHC)-related mortality generally results from cirrhosis and subsequent complications. We aimed to investigate the potential role of plasma bile acid levels and ABCB11 1331T > C (V444A, rs2287622) (ATP-binding cassette subfamily B, member 11) gene polymorphism in fibrosis prediction in CHC genotype 4 patients. MATERIALS AND METHODS: This case control study included 85 healthy control and the following 225 subjects: 170 adult patients infected with hepatitis C virus (HCV) and categorized into three groups according to liver biopsy; no fibrosis group (F0) (n=33), early fibrosis group (F1-F2) (n=61), and advanced fibrosis group (F3-F4) (n=76)...
May 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29752891/effectiveness-and-tolerability-of-direct-acting-antivirals-for-chronic-hepatitis-c-patients-in-a-southern-state-of-brazil
#6
Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Astrid Wiens, Maria Lucia Alves Pedroso, Vanessa Ferreira de Camargo Radunz, Cláudia Alexandra Pontes Ivantes, Aline Satie Oba Kuniyoshi, Roberto Pontarolo
BACKGROUND: This study aimed to evaluate the clinical effectiveness in terms of sustained virological response (SVR) and tolerability of available second generation direct-acting antivirals (DAAs) in Brazilian patients. METHODS: This was a retrospective observational study conducted in six centers in Southern Brazil. The sample comprised adult patients who were chronically infected with hepatitis C virus (HCV), regardless of virus genotype, fibrosis stage, or prior treatment...
May 9, 2018: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29750893/disparities-in-initiation-of-direct-acting-antiviral-agents-for-hepatitis-c-virus-infection-in-an-insured-population
#7
Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Pat Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk I Seo, David J Witt, Michael J Silverberg
OBJECTIVES: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. METHODS: We conducted a retrospective cohort study of HCV-infected Kaiser Permanente Northern California members aged ≥18 during October 2014 to December 2016, using Poisson regression models to evaluate demographic, behavioral, and clinical factors associated with DAA initiation...
January 1, 2018: Public Health Reports
https://www.readbyqxmd.com/read/29750037/simple-score-to-predict-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-c-patients-with-advanced-fibrosis-after-pegylated-interferon-and-ribavirin-therapy
#8
Ching-Chih Hu, Cheng-Hao Weng, Liang-Che Chang, Chih-Lang Lin, Yen-Ting Chen, Ching-Fang Hu, Man-Chin Hua, Li-Wei Chen, Rong-Nan Chien
Purpose: Eradication of chronic hepatitis C virus (HCV) after interferon-based therapy and its association with the reduction of risk of hepatocellular carcinoma (HCC) in HCV-infected patients with advanced fibrosis is controversial. The study is aimed to develop a simple scoring model for HCC prediction among advanced fibrotic chronic hepatitis C (CHC) patients after pegylated interferon (pegIFN) and ribavirin (RBV) therapy. Patients and methods: We enrolled 271 biopsy-proven CHC patients with advanced fibrosis between 2003 and 2016, and divided them into non-HCC (n=211) and HCC (n=60) groups...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29743792/effect-of-sofosbuvir-plus-daclatasvir-in-hepatitis-c-virus-genotype-4-patients-promising-effect-on-liver-fibrosis
#9
Asmaa M Abdel-Aziz, Mohamed A Ibrahim, Azza A El-Sheikh, Maha Y Kamel, Nagwa M Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem
Background/purpose: The effect of sofosbuvir and daclatasvir in treatment of genotype 4 Hepatitis C Virus (HCV) is not well documented. This study investigated the safety and efficacy of sofosbuvir plus daclatasvir with or without ribavirin in treatment of HCV genotype 4 patients. The impact of therapy on liver fibrosis as well as the role of IL18 polymorphism in therapeutic outcome was assessed. Methods: One hundred HCV genotype 4 patients were categorized into 2 groups...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743790/safety-and-efficacy-of-sofosbuvir-and-daclatasvir-for-hepatitis-c-virus-infection-in-patients-with-%C3%AE-thalassemia-major
#10
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Pankaj Desai, Vishwa Bhayani, Sanjay Patel, Viral Parekh
Background and Aims: β-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29742470/real-life-efficacy-of-ledipasvir-sofosbuvir-in-hepatitis-c-genotype-4-infected-patients-with-advanced-liver-fibrosis-and-decompensated-cirrhosis-%C3%A2-%C3%A2-%C3%A2
#11
Faisal M Sanai, Ibrahim H Altraif, Khalid Alswat, Adnan AlZanbagi, Mohamed A Babatin, Abdallah AlMousa, Nawaf H Almutairi, Mohammed S Aljawad, Abdullah S Alghamdi, Abdulrahman A Aljumah, Abduljaleel M Alalwan, Waleed K Al-Hamoudi, Abdullah M Assiri, Yaser Dahlan, Ashwaq Alsahafi, Hammad S Alothmani, Mohammed S AlSaleemi, Waleed A Mousa, Ali Albenmousa, Abdelrahman Awny, Haziz Albiladi, Ayman A Abdo, Hamdan AlGhamdi
Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SOF with or without ribavirin (RBV) in GT4-infected patients with compensated and decompensated cirrhosis. PATIENTS & METHODS: This observational cohort (n=213) included GT4 treatment-naïve (59.6%) and -experienced (40.4%) patients with advanced fibrosis (F3, Metavir; n=30), compensated (F4, n=135) and decompensated cirrhosis (n=48) treated for 12 (n=202) or 24 weeks (n=11) with LDV/SOF...
May 6, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29742149/the-il7ra-rs6897932-polymorphism-is-associated-with-progression-of-liver-fibrosis-in-patients-with-chronic-hepatitis-c-repeated-measurements-design
#12
María Ángeles Jiménez-Sousa, Ana Zaida Gómez-Moreno, Daniel Pineda-Tenor, Luz Maria Medrano, Juan José Sánchez-Ruano, Amanda Fernández-Rodríguez, Tomas Artaza-Varasa, José Saura-Montalbán, Sonia Vázquez-Morón, Pablo Ryan, Salvador Resino
The polymorphisms at the α-chain of the IL-7 receptor (IL7RA) have been related to T-cell homeostasis and development and may contribute to immune system deregulation. In the present study, we analyzed the association between IL7RA polymorphisms and the progression of liver fibrosis in patients infected with HCV. We carried out a retrospective study with a design consisting of repeated measurements in 187 HCV-infected patients, to study the risk prediction of liver fibrosis progression using genetic factors...
2018: PloS One
https://www.readbyqxmd.com/read/29737561/cryoglobulinemia-is-associated-with-advanced-liver-fibrosis-in-chronic-hepatitis-c-patients
#13
Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Po-Cheng Liang, Ming-Yen Hsieh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Pei-Lun Lee, Chia-Yen Dai
BACKGROUND AND AIM: The prevalence of mixed cryoglobulinemia (MC) is 15-50% in chronic hepatitis C (CHC) patients and these patients are in an increased risk of liver fibrosis and cirrhosis, but it is controversial. We aimed to reveal the prevalence of MC in Asian population and to determine the relationship between presence of serum cryoglobulinemia and liver fibrosis in CHC patients with or without liver biopsy. METHODS: Totally 2255 treatment naïve patients retrospectively enrolled in our study...
May 8, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29735789/direct-acting-antivirals-improve-hcv-treatment-initiation-and-adherence-among-underserved-african-americans
#14
Kendall R Beck, Nicole J Kim, Mandana Khalili
INTRODUCTION: Adherence to hepatitis C (HCV) care was suboptimal in the interferon era among underserved African Americans (AA), but adherence data in the era of direct acting antivirals (DAA) is lacking in this population. We aimed to evaluate the impact of DAA on HCV care in underserved AA. MATERIAL AND METHODS: Clinical records of AAs undergoing HCV evaluation attending a safety net health system liver clinic were reviewed from 2006 to 2011 (pre-DAA), and January 1, 2014 to December 31, 2016 (post-DAA)...
April 9, 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29727382/evaluation-of-accuracy-of-elastography-point-quantification-versus-other-noninvasive-modalities-in-staging-of-fibrosis-in-chronic-hepatitis-c-virus-patients
#15
Rabab Fouad, Tamer Elbaz, Shereen Abdel Alem, Aisha Elsharkawy, Mohamed Negm, Marwa Khairy, Mohamed Hassany, Ahmed Cordie, Wafaa El Akel, Gamal Esmat
BACKGROUND: Elastography point quantification (ElastPQ) is a newly noninvasive method incorporated into a conventional ultrasound system for staging of liver fibrosis in patients with chronic liver diseases. AIM: The aim was to evaluate ElastPQ reproducibility and its accuracy in staging of liver fibrosis in hepatitis C virus (HCV) patients in comparison with transient elastography (TE) and fibrosis scores [FIB-4 and aspartate aminotransferase-to-platelet ratio index (APRI)] using liver biopsy as a reference standard and also to predict the sensitivity and specificity of ElastPQ as well as proposing a cut-off for advanced fibrosis...
May 1, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29722445/review-article-the-prevention-of-hepatitis-b-related-hepatocellular-carcinoma
#16
REVIEW
C-L Lin, J-H Kao
BACKGROUND: Ample evidence indicates an aetiological association of persistent hepatitis B virus (HBV) infection with hepatocellular carcinoma (HCC). Several viral, host and external risk factors for the development of HBV-related HCC have been documented. AIMS: To summarise and discuss the risk stratification and the preventive strategies of HBV-related HCC. METHODS: Recent published studies identified from PubMed were comprehensively reviewed...
May 3, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29718546/improvement-of-lsm-arfi-measurements-and-non-invasive-fibrosis-markers-after-daas-for-hcv-g4-recurrence-post-living-donor-liver-transplantation-egyptian-cohort
#17
Shereen Abdel Alem, Mohamed Said, Ismail Anwar, Zeinab Abdellatif, Tamer Elbaz, Rasha Eletreby, Mahmoud AbouElKhair, Magdy El-Serafy, Sherif Mogawer, Mona El-Amir, Mostafa El-Shazly, Adel Hosny, Ayman Yosry
BACKGROUND: Progression of recurrent hepatitis C is accelerated in liver transplant (LT) recipients. Direct acting antivirals (DAAs) have recently emerged as a promising therapeutic regimen for the treatment of hepatitis C virus (HCV) infection. Rates of sustained virological response (SVR) have drastically improved since introduction of DAAs. AIM: To elucidate the changes in liver stiffness measurement (LSM) by Transient elastography (TE) as well as ARFI elastography and fibrosis scores after DAAs treatment in LT recipients with hepatitis C virus (HCV) recurrence...
May 2, 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29718134/the-gut-liver-axis-in-hepatitis-c-virus-infection-a-path-towards-altering-the-natural-history-of-fibrosis-progression
#18
Eric G Meissner
No abstract text is available yet for this article.
May 1, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29712495/development-of-a-novel-diagnostic-algorithm-to-predict-nash-in-hcv-positive-patients
#19
Andrea Gallotta, Laura Paneghetti, Viera Mrázová, Adriana Bednárová, Dáša Kružlicová, Vladimir Frecer, Stanislav Miertus, Alessandra Biasiolo, Andrea Martini, Patrizia Pontisso, Giorgio Fassina
Non-alcoholic steato-hepatitis (NASH) is a severe disease characterised by liver inflammation and progressive hepatic fibrosis, which may progress to cirrhosis and hepatocellular carcinoma. Clinical evidence suggests that in hepatitis C virus patients steatosis and NASH are associated with faster fibrosis progression and hepatocellular carcinoma. A safe and reliable non-invasive diagnostic method to detect NASH at its early stages is still needed to prevent progression of the disease. We prospectively enrolled 91 hepatitis C virus-positive patients with histologically proven chronic liver disease: 77 patients were included in our study; of these, 10 had NASH...
April 1, 2018: International Journal of Biological Markers
https://www.readbyqxmd.com/read/29709461/different-biochemical-patterns-in-type-ii-and-type-iii-mixed-cryoglobulinemia-in-hcv-positive-patients
#20
Umberto Basile, Francesca Gulli, Laura Gragnani, Krizia Pocino, Cecilia Napodano, Luca Miele, Stefano Angelo Santini, Mariapaola Marino, Anna Linda Zignego, Gian Ludovico Rapaccini
BACKGROUND: Reversible cryoprecipitability of proteins is observed as a concomitant feature of immune complex formation. Mixed cryoglobulinemia (MC) is systemic vasculitis, associated with mixed IgM and IgG cryoglobulins (CGs) showing rheumatoid factor (RF) activity. It is frequently associated with hepatitis C virus (HCV). This study investigates the presence of IgG RF and anti-nuclear antibodies (ANA) in cryoprecipitates of patients with type III and type II MC, to understand the biochemical patterns associated with different types of MC to a greater degree...
April 4, 2018: Digestive and Liver Disease
keyword
keyword
94653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"